No data available for drug.
DRUG INTERACTION
No drug interaction found for dihydroergocornine and .
nitroglycerin
may decrease the vasodilatory effect when combined with nitroglycerin
droxidopa
they increase the effect of vasoconstriction of alpha-1 agonists
droxidopa
may have an increased vasoconstricting effect when combined with alpha1-agonists
guanfacine
may have an increased vasoconstricting effect when combined with alpha1-agonists
lofexidine
may have an increased vasoconstricting effect when combined with alpha1-agonists
methyldopa
may have an increased vasoconstricting effect when combined with alpha1-agonists
tizanidine
may have an increased vasoconstricting effect when combined with alpha1-agonists
clonidine
may have an increased vasoconstricting effect when combined with alpha1-agonists
phenylephrine
may have an increased vasoconstricting effect when combined with alpha1-agonists
almotriptan
may enhance the vasoconstricting effect of ergot Derivatives
eletriptan
may enhance the vasoconstricting effect of ergot Derivatives
frovatriptan
may enhance the vasoconstricting effect of ergot Derivatives
sumatriptan
may enhance the vasoconstricting effect of ergot Derivatives
zolmitriptan
may enhance the vasoconstricting effect of ergot Derivatives
naphazoline
may increase the vasoconstriction effect of sympathomimetic drugs
fluconazole
may enhance the serum concentration of CYP3A4 inhibitors
lenacapavir
may increase the levels of serum concentration of ergot derivatives
abiraterone
may increase the levels of serum concentration of ergot derivatives
mibefradil
may increase the levels of serum concentration of ergot derivatives
citalopram
may increase the levels of serum concentration of ergot derivatives
efavirenz
may increase the levels of serum concentration of ergot derivatives
lenacapavir
may increase the levels of serum concentration of ergot derivatives
rizatriptan
may increase the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists (Triptans)
delavirdine
may enhance the concentration of serum when combined with ergot derivatives
dihydroergotamine
may have an increased vasoconstricting effect when combined with dihydroergotamine
erythromycin
may enhance the concentration of serum when combined with ergot derivatives
fosamprenavir
may enhance the concentration of serum when combined with ergot derivatives
lenacapavir
may enhance the concentration of serum when combined with ergot derivatives
letermovir
may enhance the concentration of serum when combined with ergot derivatives
lisuride
may have an increasingly adverse effect when combined with ergot derivatives
lorcaserin
may have an increasingly adverse effect when combined with ergot derivatives
nefazodone
may have an increased serotonergic effect when combined with ergot derivatives
roxithromycin
may enhance the concentration of serum when combined with ergot derivatives
bromocriptine
ergot derivatives increase the toxicity of bromocriptine
fexinidazole
it increases the concentration of ergot derivatives in serum
dexfenfluramine
ergot Derivatives may enhance the serotonergic effect of serotonergic Agents
levalbuterol
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
acebutolol
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
penbutolol
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
pindolol
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
propranolol
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
lenacapavir
may increase the levels of serum concentration
abiraterone
may increase the levels of serum concentration
mibefradil
may increase the levels of serum concentration
citalopram
may increase the levels of serum concentration
efavirenz
may increase the levels of serum concentration
maralixibat
may increase the levels of serum concentration
lenacapavir
may increase the levels of serum concentration
curcumin
may increase the levels of serum concentration
glecaprevir
may increase the levels of serum concentration
caspofungin
may increase the levels of serum concentration
efavirenz
may increase the levels of serum concentration
propofol
may increase the levels of serum concentration
maralixibat
may increase the levels of serum concentration
lenacapavir
may increase the levels of serum concentration
diacerein
may increase the levels of serum concentration
dexfenfluramine
may have an increased serotonergic effect when combined with serotonergic agents
ambrisentan (Rx)
It may diminish the metabolism when combined with Ergot alkaloids
bosentan
It may diminish the metabolism when combined with Ergot alkaloids
macitentan
It may diminish the metabolism when combined with Ergot alkaloids
estropipate
It may diminish the metabolism when combined with Ergot alkaloids
anastrozole
It may diminish the metabolism when combined with Ergot alkaloids
exemestane
It may diminish the metabolism when combined with Ergot alkaloids
formestane
It may diminish the metabolism when combined with Ergot alkaloids
altretamine
It may diminish the metabolism when combined with Ergot alkaloids
thiotepa
It may diminish the metabolism when combined with Ergot alkaloids
estrone sulfate
It may diminish the metabolism when combined with Ergot alkaloids
medroxyprogesterone
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
megestrol
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
ethinyl estradiol
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
levonorgestrel
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
lynestrenol
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
fluvoxamine
it may increase the effect of serotonergic agents
levalbuterol
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
acebutolol
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
sotalol
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
timolol
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
betaxolol
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
curcumin
may increase the serum concentration of ergot derivatives
glecaprevir
may increase the serum concentration of ergot derivatives
caspofungin
may increase the serum concentration of ergot derivatives
abiraterone
may increase the serum concentration of ergot derivatives
mibefradil
may increase the serum concentration of ergot derivatives
acebutolol
may increase the effect of ergot derivatives
penbutolol
may increase the effect of ergot derivatives
pindolol
may increase the effect of ergot derivatives
propranolol
may increase the effect of ergot derivatives
mirabegron
may increase the vasoconstricting effect
penbutolol
may increase the vasoconstricting effect
betaxolol
may increase the vasoconstricting effect
bisoprolol
may increase the vasoconstricting effect
carvedilol
may increase the vasoconstricting effect
timolol
may increase the vasoconstricting effect
pergolide
may have an increasingly adverse effect when combined with ergot derivatives
reboxetine
may have an increased hypertensive effect when combined with ergot derivatives
chloroprocaine
it increases the effect of hypertension of ergot derivatives
ambrisentan (Rx)
It may diminish the metabolism when combined with Endothelin antagonists
bosentan
It may diminish the metabolism when combined with Endothelin antagonists
macitentan
It may diminish the metabolism when combined with Endothelin antagonists
estropipate
It may diminish the metabolism when combined with Estrogens
anastrozole
It may diminish the metabolism when combined with Estrogens
altretamine
It may diminish the metabolism when combined with Ethylenimine
thiotepa
It may diminish the metabolism when combined with Ethylenimine
hydralazine
It may diminish the metabolism when combined with Vasodilators
No data available for drug.
DRUG INTERACTION
dihydroergocornine
&
No Drug Intearction Found. for dihydroergocornine and .
nitroglycerin
may decrease the vasodilatory effect when combined with nitroglycerin
droxidopa
they increase the effect of vasoconstriction of alpha-1 agonists
droxidopa
may have an increased vasoconstricting effect when combined with alpha1-agonists
guanfacine
may have an increased vasoconstricting effect when combined with alpha1-agonists
lofexidine
may have an increased vasoconstricting effect when combined with alpha1-agonists
methyldopa
may have an increased vasoconstricting effect when combined with alpha1-agonists
tizanidine
may have an increased vasoconstricting effect when combined with alpha1-agonists
clonidine
may have an increased vasoconstricting effect when combined with alpha1-agonists
phenylephrine
may have an increased vasoconstricting effect when combined with alpha1-agonists
almotriptan
may enhance the vasoconstricting effect of ergot Derivatives
eletriptan
may enhance the vasoconstricting effect of ergot Derivatives
frovatriptan
may enhance the vasoconstricting effect of ergot Derivatives
sumatriptan
may enhance the vasoconstricting effect of ergot Derivatives
zolmitriptan
may enhance the vasoconstricting effect of ergot Derivatives
naphazoline
may increase the vasoconstriction effect of sympathomimetic drugs
fluconazole
may enhance the serum concentration of CYP3A4 inhibitors
lenacapavir
may increase the levels of serum concentration of ergot derivatives
abiraterone
may increase the levels of serum concentration of ergot derivatives
mibefradil
may increase the levels of serum concentration of ergot derivatives
citalopram
may increase the levels of serum concentration of ergot derivatives
efavirenz
may increase the levels of serum concentration of ergot derivatives
lenacapavir
may increase the levels of serum concentration of ergot derivatives
rizatriptan
may increase the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists (Triptans)
delavirdine
may enhance the concentration of serum when combined with ergot derivatives
dihydroergotamine
may have an increased vasoconstricting effect when combined with dihydroergotamine
erythromycin
may enhance the concentration of serum when combined with ergot derivatives
fosamprenavir
may enhance the concentration of serum when combined with ergot derivatives
lenacapavir
may enhance the concentration of serum when combined with ergot derivatives
letermovir
may enhance the concentration of serum when combined with ergot derivatives
lisuride
may have an increasingly adverse effect when combined with ergot derivatives
lorcaserin
may have an increasingly adverse effect when combined with ergot derivatives
nefazodone
may have an increased serotonergic effect when combined with ergot derivatives
roxithromycin
may enhance the concentration of serum when combined with ergot derivatives
bromocriptine
ergot derivatives increase the toxicity of bromocriptine
fexinidazole
it increases the concentration of ergot derivatives in serum
dexfenfluramine
ergot Derivatives may enhance the serotonergic effect of serotonergic Agents
levalbuterol
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
acebutolol
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
penbutolol
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
pindolol
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
propranolol
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
lenacapavir
may increase the levels of serum concentration
abiraterone
may increase the levels of serum concentration
mibefradil
may increase the levels of serum concentration
citalopram
may increase the levels of serum concentration
efavirenz
may increase the levels of serum concentration
maralixibat
may increase the levels of serum concentration
lenacapavir
may increase the levels of serum concentration
curcumin
may increase the levels of serum concentration
glecaprevir
may increase the levels of serum concentration
caspofungin
may increase the levels of serum concentration
efavirenz
may increase the levels of serum concentration
propofol
may increase the levels of serum concentration
maralixibat
may increase the levels of serum concentration
lenacapavir
may increase the levels of serum concentration
diacerein
may increase the levels of serum concentration
dexfenfluramine
may have an increased serotonergic effect when combined with serotonergic agents
ambrisentan (Rx)
It may diminish the metabolism when combined with Ergot alkaloids
bosentan
It may diminish the metabolism when combined with Ergot alkaloids
macitentan
It may diminish the metabolism when combined with Ergot alkaloids
estropipate
It may diminish the metabolism when combined with Ergot alkaloids
anastrozole
It may diminish the metabolism when combined with Ergot alkaloids
exemestane
It may diminish the metabolism when combined with Ergot alkaloids
formestane
It may diminish the metabolism when combined with Ergot alkaloids
altretamine
It may diminish the metabolism when combined with Ergot alkaloids
thiotepa
It may diminish the metabolism when combined with Ergot alkaloids
estrone sulfate
It may diminish the metabolism when combined with Ergot alkaloids
medroxyprogesterone
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
megestrol
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
ethinyl estradiol
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
levonorgestrel
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
lynestrenol
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
fluvoxamine
it may increase the effect of serotonergic agents
levalbuterol
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
acebutolol
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
sotalol
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
timolol
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
betaxolol
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
curcumin
may increase the serum concentration of ergot derivatives
glecaprevir
may increase the serum concentration of ergot derivatives
caspofungin
may increase the serum concentration of ergot derivatives
abiraterone
may increase the serum concentration of ergot derivatives
mibefradil
may increase the serum concentration of ergot derivatives
acebutolol
may increase the effect of ergot derivatives
penbutolol
may increase the effect of ergot derivatives
pindolol
may increase the effect of ergot derivatives
propranolol
may increase the effect of ergot derivatives
mirabegron
may increase the vasoconstricting effect
penbutolol
may increase the vasoconstricting effect
betaxolol
may increase the vasoconstricting effect
bisoprolol
may increase the vasoconstricting effect
carvedilol
may increase the vasoconstricting effect
timolol
may increase the vasoconstricting effect
pergolide
may have an increasingly adverse effect when combined with ergot derivatives
reboxetine
may have an increased hypertensive effect when combined with ergot derivatives
chloroprocaine
it increases the effect of hypertension of ergot derivatives
ambrisentan (Rx)
It may diminish the metabolism when combined with Endothelin antagonists
bosentan
It may diminish the metabolism when combined with Endothelin antagonists
macitentan
It may diminish the metabolism when combined with Endothelin antagonists
estropipate
It may diminish the metabolism when combined with Estrogens
anastrozole
It may diminish the metabolism when combined with Estrogens
altretamine
It may diminish the metabolism when combined with Ethylenimine
thiotepa
It may diminish the metabolism when combined with Ethylenimine
hydralazine
It may diminish the metabolism when combined with Vasodilators
medtigo
Action and Spectrum
Drug Interaction
Adverse Reaction
Black Box Warning
Contraindication / Caution
Pregnancy / Lactation
Pharmacology
Adminstartion
Patient Information Leaflet